Table 1.
Lipid content in microvesicles and enrichment as compared to the originating cells. Data are expressed as percent of total lipid quantified and as MV/cell ratios (brackets), except when specified. Percentages or ratios were calculated from raw data when furnished or estimated on graphs. MS, mass spectrometry; TLC, thin layer chromatography; PM, plasma membrane; -, not determined; SM, sphingomyelin; Cer, ceramide; PC, phosphatidylcholine; PS, phosphatidylserine; PE, phosphatidylethanolamine; chol, cholesterol; PLPs, phospholipids.
| Cell Type/Body Fluid | Lipid Analysis | MV Size (nm) | % of Total Lipid Content (MV/Cell Ratio) | Ref. | |||||
|---|---|---|---|---|---|---|---|---|---|
| SM | Cer | PC | PS | PE | Chol/PLPs | ||||
| U87 glioblastoma cells | MS | 50–600 | 15% (2) | 0.7% (2.4) | 25% (0.9) | 17% (1) | 9.6% (0.9) | - | [88] |
| Huh7 hepatocellular carcinoma cells | MS | 50–600 | 15% (3.6) | 0.3% (1.5) | 27% (1.3) | 7.4% (0.6) | 6.8% (0.7) | - | [88] |
| Bone marrow derived stem cells | MS | 50–600 | 8.6% (1.6) | 0.5% (1.9) | 25% (1.2) | 8% (0.7) | 3.7% (0.5) | - | [88] |
| Placenta | MS | - | 37% | 1% | 15% | 17% | 2% | - | [89] |
| Plasma EVs (ratio on platelets) | TLC | - | 21% (1) | - | 59% (1.8) | 3.6% (0.3) | 9.4% (0.3) | - | [90] |
| Stored RBCs (53 ± 4 days) | MS | - | (1) | - | (1) | (7) | (0.8) | - | [91] |
| Stored RBCs (35–42 days) | MS | 100–300 | 33% (1) | - | 26% (1) | 10% (1) | 30% (1) | - | [92] |
| ATP-depleted RBCs | Enzymatic | ~200 | 26% (0.9) | - | 27% (0.9) | - | 25% (0.8) | (0.9) | [93] |
| Platelets | MS | - | 14% (1.3) | 0.7% (1.3) | 27% (0.7) | 17% (1) | 37% (1) | - | [94] |
| Platelets (ratio on PM platelets) | TLC | - | 25% (1.1) | - | 31% (1.1) | 14% (0.8) | 30% (1) | (1.5) | [95] |